Table 2 Robo1 BiCAR- NK92-mediated immunotherapy tested in phase I/II clinical trials in patients with relapsed and refractory pancreatic cancer
Clinical trial identifier | Target antigen | Condition or disease | Origin of NK cell | Construct | Phase | Status | Location |
|---|---|---|---|---|---|---|---|
NCT03824964 | CD19/CD22 | Refractory B cell lymphoma | Allogeneic NK cells | Not mentioned | Early phase I | Not yet recruiting | Not mentioned |
NCT03940833 | BCMA | Multiple myeloma | NK 92 cells | Not mentioned | I/II | Recruiting | Suzhou, Jiangsu, China |
NCT02892695 | CD19 | Lymphoma and leukemia | NK 92 cells | Not mentioned | I/II | Unknown | Suzhou, Jiangsu, China |
NCT03579927 | CD19 | Lymphoma and leukemia | Cord Blood NK Cells | CAR.CD19-CD28-zeta-2A-iCasp9-IL15 | I/II | Not yet recruiting | Houston, TX, USA |
NCT03692663 | PSMA | Castration-resistant Prostate Cancer | Not specified | Not mentioned | Early phase I | Not yet recruiting | Not mentioned |
NCT03692637 | Mesothelin | Epithelial ovarian cancer | Not specified | Not mentioned | Early phase I | Not yet recruiting | Not mentioned |
NCT03941457 | ROBO1 | Pancreatic cancer | Not specified | BiCAR-NK cells | I/II | Recruiting | Shanghai, China |
NCT03940820 | ROBO1 | Solid tumor | Not specified | Not mentioned | I/II | Recruiting | Suzhou, Jiangsu, China |
NCT03415100 | NKG2D ligands | Solid tumors | Autologous or allogeneic NK cells | Not mentioned | I | Recruiting | Guangzhou, Guangdong, China |
NCT03056339 | CD19 | Lymphoma and leukemia (relapsed/refractory B cell malignancy) | Umbilical cord blood I | CAR.CD19-CD28-zeta-2A-iCasp9-IL15 | I/II | Recruiting | Houston, TX, USA |
NCT02944162 | CD33 | Acute myeloid leukemia (AML) | NK 92 cells | CAR.CD28, CD137 and CD3 zeta | I/II | Unknown | Suzhou, Jiangsu, China |
NCT03931720 | ROBO1 | Malignant tumor | Not specified | BiCAR-NK/T cells | I/II | Recruiting | Suzhou, Jiangsu, China |
NCT03692767 | CD22 | Refractory B cell lymphoma | Allogeneic NK cells | Not mentioned | Early phase I | Not yet recruiting | Not mentioned |
NCT03690310 | CD19 | Refractory B cell lymphoma | Allogeneic NK cells | Not mentioned | Early phase I | Not yet recruiting | Not mentioned |
NCT01974479 | CD19 | All | Haploidentical donor NK cells | Not mentioned | I | Suspended | Singapore |
NCT00995137 | CD19 | All | Expanded donor NK cells | Not mentioned | I | Completed | Memphis, TN, USA |